Coronary disease & ACS

Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary Syndrome

JACC Cardiovasc IntervPublished Secondary analysis of the ALPHEUS randomised trial

Primary result · PCI-related MI or major injuryResult — go to the resultOdds ratio 0.73 95% CI 0.60–0.88

Authors' conclusion

Clopidogrel-naive patients presented less periprocedural complications compared to clopidogrel(+) patients, a difference related to a lower risk profile and less complex PCI.

Study context

Population
Patients undergoing elective percutaneous coronary intervention (PCI)
Participants
1,882 patients
Comparison
Ticagrelor vs clopidogrel, by chronic clopidogrel therapy before elective PCI
  • Clopidogrel(+)n = 805reference
Primary endpoint
Composite of:
  • PCI-related MI
  • Major injury (third and fourth universal definition)
Follow-up
48 hours after PCI
Methodological detailsprespecified analysis
  • Prespecified analysis

Primary result

PCI-related MI or major injury

Odds ratio

0.73

95% CI 0.60–0.88

By group

Clopidogrel(-)vs clopidogrel(+)
OR 0.73 (95% CI 0.60–0.88)

As reported in the abstract

Further findings

Death, MI, stroke or TIA · 48 hours or 30 days

No significant differences between clopidogrel(-) and clopidogrel(+)

Original publication

Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary Syndrome. JACC Cardiovasc Interv. Published 5 June 2024. doi:10.1016/j.jcin.2024.04.015

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.